Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| TREACE MEDICAL CONCEPTS, INC.TMCI · Entity 5943 | Chief Commercial Officer | January 22, 2026 | January 23, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
TREACE MEDICAL CONCEPTS, INC.
Report date January 22, 2026 · Filed January 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 490,901 |
Reported balance
After 2026-01-22 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-01-22 · Grant · Acquired 150,000 · Balance 490,901 F1: Represents restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of issuer's Common Stock for each RSU upon vesting. The RSUs vest in equal annual installments over 4 years, with the first installment vesting on January 22, 2027 and the last installment vesting on January 22, 2030; subject to Reporting Person's providing continued service to Issuer through each vesting date. F2: Includes 422,250 restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of issuer's Common Stock for each RSU upon vesting. The RSUs vest in equal annual installments over 4 years, with the first installment vesting on January 22, 2027 and the last installment vesting on January 22, 2030; subject to Reporting Person's providing continued service to Issuer through each vesting date.
F2: Includes 422,250 restricted stock units.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 22, 2026 Filed Jan 23, 2026 21:30 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | GrantCommon Stock | 150,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-021453 · ownership.xml · nonDerivative · entry 1 Guglielmino Gaetano · CIK 0002047624 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 490,901 F1 · shares: Represents restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of issuer's Common Stock for each RSU upon vesting. The RSUs vest in equal annual installments over 4 years, with the first installment vesting on January 22, 2027 and the last installment vesting on January 22, 2030; subject to Reporting Person's providing continued service to Issuer through each vesting date. F2 · balance_after: Includes 422,250 restricted stock units. Read SEC document |
| December 01, 2025 Filed Dec 3, 2025 21:00 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | Tax withholdingCommon Stock | 2,009 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-307269 · ownership.xml · nonDerivative · entry 2 Guglielmino Guy · CIK 0002047624 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 340,901 F2 · balance_after: Includes 272,250 restricted stock units. Read SEC document |
| December 01, 2025 Filed Dec 3, 2025 21:00 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | Tax withholdingCommon Stock | 20,090 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-307269 · ownership.xml · nonDerivative · entry 1 Guglielmino Guy · CIK 0002047624 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 342,910 F1 · balance_after: Includes 280,500 restricted stock units. Read SEC document |
| December 01, 2024 Filed Dec 5, 2024 16:30 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | GrantCommon Stock | 33,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-133720 · ownership.xml · nonDerivative · entry 2 Guglielmino Guy · CIK 0002047624 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 363,000 F3 · shares: Represents restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of issuer's Common Stock for each RSU upon vesting. The RSUs vest in four equal annual installments on the first, second, third and fourth anniversaries of the grant date; subject to Reporting Person's providing continued service to Issuer through each vesting date. These RSUs represented a portion of the executive's signing bonus which was granted in equity rather than in cash. F4 · balance_after: Includes 363,000 RSUs. Read SEC document |
| December 01, 2024 Filed Dec 5, 2024 16:30 UTC | TREACE MEDICAL CONCEPTS, INC. TMCI · Entity 5943 | GrantCommon Stock | 330,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-133720 · ownership.xml · nonDerivative · entry 1 Guglielmino Guy · CIK 0002047624 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 330,000 F1 · shares: Represents restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of issuer's Common Stock for each RSU upon vesting. The RSUs vest in four equal annual installments on the first, second, third and fourth anniversaries of the grant date; subject to Reporting Person's providing continued service to Issuer through each vesting date. F2 · balance_after: includes 330,000 RSUs. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.